Neoleukin Therapeutics Inc logo

NLTX

Neoleukin Therapeutics Inc

$1.07

Earnings Summary

Revenue
$0Mn
Net Profits
$-15.35Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Neoleukin Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Neoleukin Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Neoleukin Therapeutics Inc’s net profit fell -2.68% since last year same period to $-15.35Mn in the Q1 2022. On a quarterly growth basis, Neoleukin Therapeutics Inc has generated -1.21% fall in its net profits since last 3-months.

Net Profit Margins:

Neoleukin Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Neoleukin Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Neoleukin Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.3
EPS Estimate Current Year
-0.3

Highlights

EPS Estimate Current Quarter:

Neoleukin Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.3 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Neoleukin Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.3.

Key Ratios

Key ratios of the Neoleukin Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.28
Return on Assets (ROA)
-0.24
Return on Equity (ROE)
-0.43
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Neoleukin Therapeutics Inc’s earning per share (EPS) fell -3.7% since last year same period to -0.28 in the Q1 2022. This indicates that the Neoleukin Therapeutics Inc has generated -3.7% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Neoleukin Therapeutics Inc’s return on assets (ROA) stands at -0.24.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Neoleukin Therapeutics Inc’s return on equity (ROE) stands at -0.43.

Dividend Per Share (DPS):

Neoleukin Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.3
-0.28
6.67%

Company Information

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface.

Organisation
Neoleukin Therapeutics Inc
Employees
70
Industry
Health Technology